SCHEMBL422506

SCHEMBL422506

CCOC(=O)c1ccc(N2C(=O)NC(=O)C23CCCCC3)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 5/20 0.49
ALDH1A1 P00352 3/20 0.49
HPGD P15428 2/20 0.49
NPSR1 Q6W5P4 2/20 0.49
HSP90AA1 P07900 1/20 0.49
CACNA1B Q00975 1/20 0.49
APBA1 Q02410 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
MAPK1 P28482 1/20 0.48
LMNA P02545 3/20 0.47
IDO1 P14902 1/20 0.45
GAA P10253 3/20 0.44
SMN1; SMN2 Q16637 4/20 0.43
NPC1 O15118 3/20 0.43
RAB9A P51151 2/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
ESR1 P03372 1/20 0.43
CA7 P43166 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL201840 0.78 POLB (0.51) ALDH1A1MAPK1SMN1; SMN2NPC1RAB9A
SCHEMBL190640 0.74 ALDH1A1 (0.55) ALDH1A1HPGDNPSR1MAPK1LMNA
Cyclohexane SCHEMBL2917907 0.74 CA1 (0.73) HTTALDH1A1HPGDNPSR1HSP90AA1
SCHEMBL76936 0.72 ALDH1A1 (0.49) HTTALDH1A1HPGDNPSR1HSP90AA1
SCHEMBL421867 0.72 AKR1B1 (0.37) HTTALDH1A1HPGDMAPK1LMNA
SCHEMBL17077228 0.72 MAPT (0.45) ALDH1A1NPC1MAPT
SCHEMBL18961831 0.72 LMNA (0.46) LMNAGAASMN1; SMN2MAPT
SCHEMBL3900474 0.71 SIRT2 (0.60) HTTALDH1A1HPGDNPSR1HSP90AA1
SCHEMBL6132930 0.70 HPGD (0.51) HTTALDH1A1HPGDNPSR1HSP90AA1
SCHEMBL2544529 0.70 MMP13 (0.46) LMNAGAASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420682-B2 N-phenylacetamide derivatives, which inhibit the enzyme SOAT-1, and pharmaceutical and cosmetic compositions containing them GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-04-16 US disclosed
US-20120021017-A1 N-PHENYLACETAMIDE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM GALDERMA RESEARCH & DEVELOPMENT (FR) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120021017-A1 N-PHENYLACETAMIDE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM SOAT1, SOAT2, NAT1 HTT 1730/4885ALDH1A1 47/4885HPGD 797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.